TNYA News and Press, Tenaya Therapeutics Inc. From 05/19/22

Gainers: NeuroMetrix (NURO) +34%. Millicom International (TIGO) +32%. Grab Holdings (GRAB) +30%. SIGA Technologies (SIGA) +26%. Celyad Oncology (CYAD) +19%. Clene (CLNN) +19%. Applied Blockchain (APLD) +19%. Immunome (IMNM) +18%. BIT Mining (BTCM) +18%. Losers: Companhia Energetica de Minas G...

Tenaya Therapeutics press release (NASDAQ:TNYA): Q1 GAAP EPS of $0.75 beats by $1.42. Cash and cash equivalents of $213.5M For further details see: Tenaya Therapeutics GAAP EPS of $0.75 beats by $1.42

TN-201 Received Orphan Medicinal Product Designation from the European Commission Preclinical TN-401 Data Presented at Heart Rhythm 2022 Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially cura...

ASGCT Presentations Include Preclinical Data for TN-401 PKP2 and DWORF Gene Therapy Programs and AAV Capsid Engineering Innovations Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that addre...

Abstract Detailing TN-401 Results in PKP2 Mouse Model Accepted for Late-Breaker Oral Presentation TN-401 IND-Enabling Studies Ongoing, On Track to Submit IND in 2023 Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

The following slide deck was published by Tenaya Therapeutics, Inc. in conjunction with this event. For further details see: Tenaya Therapeutics (TNYA) Investor Presentations - Slideshow

Tenaya Therapeutics press release (NASDAQ:TNYA): Q4 GAAP EPS of -$0.63 beats by $0.15. As of December 31, 2021, cash, cash equivalents and investments in marketable securities were $251.3 million, compared to $128.5 million as of December 31, 2020. For further details see: Tenaya Therap...

Strengthened Leadership Team with the Additions of Sunita Sethi as Senior Vice President of Regulatory Affairs and Naymisha Patel as Senior Vice President of Quality Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and del...

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced participation at several upcoming investor conferences. Details of each presentati...